Avalo Therapeutics, Inc. · NASDAQ:AVTX

Avalo Therapeutics — Investor Presentation (October 2025)

21 slides from Avalo Therapeutics's investor presentation, Oct 10, 2025

  1. Slide 1: Corporate Overview October 2025

    ne mission. Advancing an inspired pipeline of novel IL-1β therapies focused on treating unmet medical needs. CORPORATE OVERVIEW OCTOBER 2025 | AVALO THERAPEUTICS, INC. (AVTX) Exhibit 99.1

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements This presentation may include forward-looking statements made pursuant to the Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not historical facts. Such forward-looking statements are subject to significant risks and unc

  3. Slide 3: Advancing the Next-Generation of IL-1β Inhibition for Immune Mediated Inflammatory Diseases

    Avalo Therapeutics: Advancing the Next-Generation of IL-1β Inhibition for Immune Mediated Inflammatory Diseases 3 IL, interleukin; IND, investigational new drug application; mAB, monoclonal antibody; MOA, mechanism of action. 1. Vossen ARJV, et al. J Invest Dermatol. 2020;140(7):1463-1466.e2; 2. Kel

  4. Slide 4: Avalo Management Team

    Avalo Management Team 4 A proven track record of successful leadership, product development, and commercialization in pharma and biotech Lisa Hegg, PhD SVP, Program Management, Business Development & Corporate Infrastructure Colleen Matkowski SVP, Global Regulatory Affairs, Quality Assurance Dino C.

  5. Slide 5: AVTX-009: Designed to Target the Inflammatory Driver of HS

    AVTX-009: Designed to Target the Inflammatory Driver of Hidradenitis Suppurativa (HS) to Address Significant Unmet Need 5

  6. Slide 6: Chronic Inflammation in Hidradenitis Suppurativa Progresses to Tissue Destruction

    Chronic Inflammation in Hidradenitis Suppurativa Progresses to Tissue Destruction 6 Photos from Mendes-Bastos P, et al. Front Med (Lausanne). 2024;11:1403455; Ovadja ZN, et al. Brit J Dermatol. 2019;181:243-244; Cotter C, Walsh S. Skin Health and Disease. 2021;1(1):e7. CC-BY-4.0 License. 1. Diaz MJ,

  7. Slide 7: Persistent Unmet Need in HS Due to Limited Efficacy of Current Therapies

    Persistent Unmet Need in HS Due to Limited Efficacy of Current Anti- TNF and Anti-IL-17 Biologic Therapies 7 HS, hidradenitis suppurativa. aCurrent treatments include antibiotics, retinoids, steroids, Cosentyx®, Humira®. 1. Ingram JR, et al. J Eur Acad Dermatol Venereol. 2022;36(9):1597-1605; 2. Kim

  8. Slide 8: IL-1β Plays a Central Role in the Pathophysiology of HS

    IL-1β Plays a Central Role in the Pathophysiology of HS 8 DAMP, damage-associated molecular pattern molecule; DC, dendritic cell; HS, hidradenitis suppurativa; IL, interleukin; R, receptor; PAMP, pathogen-associated molecular pattern molecule. Figure adapted from Agnese ER et al. Cureus. 15(11):e493

  9. Slide 9: Lutikizumab Data Highlights the Role for IL-1 in HS

    0% 10% 20% 30% 40% 50% Phase 2 Lutikizumab Data Highlights the Role for IL-1 in HS 9 *NS, not statistically significant ; All-ABX, patients who received any systemic antibiotic (new or increased dose) or who discontinued due to an adverse event or absence of efficacy were treated as nonresponders at

  10. Slide 10: AVTX-009 Is A Highly Potent, Specific Inhibitor of IL-1β

    AVTX-009 Is A Highly Potent, Specific Inhibitor of IL-1β • Clinical experience – 245 patients studied in phase 1 and phase 2 trials2,3-6 – Significant and rapid lowering of inflammatory biomarkers after a single dose of 0.6 mg – Well-tolerated and favorable safety profile at all doses up to 180 mg S

  11. Slide 11: AVTX-009 Potential Profile Advantages vs Lutikizumab

    Specificity IL-1 (α&β) IL-1β IL-1β binding affinity 44 KD (pM) <3 KD (pM) Subcutaneous bioavailability 46% 73% Half-life 10-14 days 19 days Dosing evaluated in HS study Q1W & Q2W4 Q2W & Q4W5 AVTX-009 Potential Profile Advantages: IL-1β Specificity, Higher Affinity, Bioavailability, and Longer Half-L

  12. Slide 12: Why Specificity Matters: IL-1β is the Predominant IL-1 Isoform in HS

    0% 20% 40% 60% Why Specificity Matters: IL-1β is the Predominant IL-1 Isoform that Drives Chronic Inflammation in HS 12 HiSCR, hidradenitis suppurativa clinical response; HS, hidradenitis suppurativa; IL, interleukin; mAb, monoclonal antibody; QW, weekly, Q2W, every other week; wk, week. aFigure ada

  13. Slide 13: Why Affinity Matters in HS

    Why Affinity Matters in HS 13 mAbs, monoclonal antibodies. 1. Ryman JT & Meibohm B. CPT Pharmacometrics Syst Pharmacol. 2017.6:576-588; 2. Humira. Package insert. AbbVie Inc.; 2024; 3. Cosentyx. Package insert. Novartis Pharmaceuticals Corporation; 2024; 4. Witte-Händel E, et al. J Invest Dermatol.

  14. Slide 14: Phase 2 LOTUS Trial in Hidradenitis Suppurativa

    Phase 2 LOTUS Trial in Hidradenitis Suppurativa (AVTX-009-HS-201, NCT06603077) 14 ADA, antidrug antibody; AN, abscess and inflammatory nodule; CRP, C-reactive protein; DLQI, dermatology life quality index; EOS, end of study; EOT, end of treatment; HiSCR, Hidradenitis Suppurativa Clinical Response; H

  15. Slide 15: Diagnosed and Treated HS Population Projected to Grow into a $10B+ Global Market by 2035

    Diagnosed and Treated HS Population is Projected to Grow Substantially into a $10B+ Global Market by 20351 15 HCP, healthcare provider; HS, hidradenitis suppurativa; U.S., United States. 1. HS Market Research 2024. Avalo Therapeutics Data on File; 2. Garg A, et al. Am J Clin Dermatol. 2023;24:977-99

  16. Slide 16: Timelines: Looking Forward

    Timelines: Looking Forward 16 IND, investigational new drug application. aProjected; bPending readout from phase 2. MARCH 2024 JULY 2024 OCTOBER 2024 MID 2026 2027 Merger with AlmataBio Active IND for AVTX-009 First patient enrolled in phase 2 LOTUS LOTUS (phase 2) readouta Initiate pivotal programb

  17. Slide 17: Broad Potential for Indication Expansion

    Broad Potential for Indication Expansion: Clinical Rationale for IL-1 Targeting Therapies in Additional Disease States 17 CRP, C-reactive protein; CV, cardiovascular; DIRA, deficiency of interleukin receptor 1 antagonist; HS, hidradenitis suppurativa; IBD, inflammatory bowel disease; MI, myocardial

  18. Slide 18: Avalo Summary

    Avalo Summary (NASDAQ: AVTX) 18 IL, interleukin; mAB, monoclonal antibody. 1.Dinarello CA. Immunol Rev. 2018;281(1):8-27; 2. Bihorel S, et al. AAPS J. 2014;16(5):1009-1017; 3. Lacy SE, et al. mAbs. 2015;7(3):605-619; 2. Wang SX, et al. Osteoarthritis Cartilage. 2017;25(12):1952-1961; 4. Clinicaltria

  19. Slide 19: www.avalotx.com

    NASDAQ: AVTX www.avalotx.com 19

  20. Slide 20: Appendix

    avalo THERAPEUTIGS Appendix

  21. Slide 21: Key Financial Metrics

    Key Financial Metrics 21 1. Does not include 5.3M of stock options, restricted stock units and performance stock units outstanding resulting in a fully dilutive share count of 42.5M as of September 30, 2025, 2. Cash, cash equivalents and short- term investments, common shares outstanding, and prefer

Avalo Therapeutics — Investor Presentation (October 2025) on 6ix